Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 100
Summary
- Conditions
- HIV -1 Infection
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Participants will be enrolled into Cohort 2 if Cohort 1 is fully enrolled or if they do not meet the criteria for randomization in Cohort 1.Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Knowledge of treatment assignments will be masked during the Functional Monotherapy Period in Cohort 1.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 12 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04150068
- Collaborators
- Not Provided
- Investigators
- Study Director: Gilead Study Director Gilead Sciences
Get Well Soon